ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.
Many promising tests have already been carried out on mouses.
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.
The Financement of this research will be done through a platform of "crowdfunding".
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
- Bruno Vigneron
- Image Size
- 5000x2810 / 8.8MB
- Contained in galleries